➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
McKinsey
Medtronic
Dow
Baxter

Last Updated: May 27, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DIPHTHERIA AND TETANUS TOXOIDS ADSORBED

» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for DIPHTHERIA AND TETANUS TOXOIDS ADSORBED

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00707148 Pertussis Vaccine in Healthy Pregnant Women Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 1 2009-01-01 The purpose of this study is to look at the safety and immunogenicity of a combination vaccine that includes tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap). The study will be conducted in 48 pregnant women and 32 non-pregnant women. Safety of the newborn infant and the effect of the mother's vaccination on the infants' immune responses prior to vaccinating infants with another combination vaccine to protect against diphtheria, tetanus, and pertussis will be evaluated. Participants will be 18-45 years old. Pregnant volunteers will be 30-32 weeks pregnant and at a low risk for pregnancy complications. Pregnant volunteers will receive 2 injections (1 vaccine and 1 placebo, inactive substance); non-pregnant volunteers will receive 1 injection of vaccine. Blood samples will be collected from the mother and infant, along with the baby's growth measurements. Participation for mother infant pairs is about 15 months and about 7 months for non-pregnant women.
NCT02529072 Nivolumab With DC Vaccines for Recurrent Brain Tumors Recruiting Bristol-Myers Squibb Phase 1 2016-01-01 Patients will be randomized to one of two treatment arms - Group I and Group II. Group I will receive nivolumab monotherapy until surgical resection, and Group II will receive nivolumab alone and with DC vaccine therapy until surgical resection. During surgical resection blood and tumor samples will be assessed and compared. Following surgery, both groups will continue to receive DC vaccines (total of 8) and nivolumab therapy until confirmed progression.
NCT02529072 Nivolumab With DC Vaccines for Recurrent Brain Tumors Recruiting Duke Cancer Institute Phase 1 2016-01-01 Patients will be randomized to one of two treatment arms - Group I and Group II. Group I will receive nivolumab monotherapy until surgical resection, and Group II will receive nivolumab alone and with DC vaccine therapy until surgical resection. During surgical resection blood and tumor samples will be assessed and compared. Following surgery, both groups will continue to receive DC vaccines (total of 8) and nivolumab therapy until confirmed progression.
NCT02529072 Nivolumab With DC Vaccines for Recurrent Brain Tumors Recruiting Gary Archer Ph.D. Phase 1 2016-01-01 Patients will be randomized to one of two treatment arms - Group I and Group II. Group I will receive nivolumab monotherapy until surgical resection, and Group II will receive nivolumab alone and with DC vaccine therapy until surgical resection. During surgical resection blood and tumor samples will be assessed and compared. Following surgery, both groups will continue to receive DC vaccines (total of 8) and nivolumab therapy until confirmed progression.
NCT03927222 Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma Not yet recruiting Gary Archer Ph.D. Phase 2 2019-06-01 This is a single-arm phase II study for newly-diagnosed WHO Grade IV glioblastoma patients who have undergone definitive tumor resection, are unmethylated, and completed standard chemoradiation treatment. After completion of the standard of care radiotherapy with concurrent temozolomide (TMZ), patients will receive 1 cycle of dose-intensified TMZ followed by serial vaccines of cytomegalovirus pp65-loaded dendritic cells (DCs) beginning on day 23 with tetanus and GM-CSF vaccine site pre-conditioning. All enrolled patients will undergo a leukapheresis after tumor resection for the generation of DCs. All patients will receive up to a total of 10 DC vaccines every 28 days (± 2 days) given bilaterally at the groin site.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for DIPHTHERIA AND TETANUS TOXOIDS ADSORBED

Condition Name

Condition Name for DIPHTHERIA AND TETANUS TOXOIDS ADSORBED
Intervention Trials
Glioblastoma 2
Pertussis 1
Malignant Glioma 1
Diphtheria 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for DIPHTHERIA AND TETANUS TOXOIDS ADSORBED
Intervention Trials
Glioblastoma 2
Brain Neoplasms 1
Astrocytoma 1
Whooping Cough 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for DIPHTHERIA AND TETANUS TOXOIDS ADSORBED

Trials by Country

Trials by Country for DIPHTHERIA AND TETANUS TOXOIDS ADSORBED
Location Trials
United States 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for DIPHTHERIA AND TETANUS TOXOIDS ADSORBED
Location Trials
North Carolina 3
Washington 1
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for DIPHTHERIA AND TETANUS TOXOIDS ADSORBED

Clinical Trial Phase

Clinical Trial Phase for DIPHTHERIA AND TETANUS TOXOIDS ADSORBED
Clinical Trial Phase Trials
Phase 2 1
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for DIPHTHERIA AND TETANUS TOXOIDS ADSORBED
Clinical Trial Phase Trials
Recruiting 1
Completed 1
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for DIPHTHERIA AND TETANUS TOXOIDS ADSORBED

Sponsor Name

Sponsor Name for DIPHTHERIA AND TETANUS TOXOIDS ADSORBED
Sponsor Trials
Gary Archer Ph.D. 2
Duke Cancer Institute 1
Bristol-Myers Squibb 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for DIPHTHERIA AND TETANUS TOXOIDS ADSORBED
Sponsor Trials
Other 3
Industry 1
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Dow
Boehringer Ingelheim
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.